Heart Failure

Cardiovascular
104
Pipeline Programs
30
Companies
50
Clinical Trials
5 recruiting
5
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
22
8
21
4
19
30
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1368%
Peptide
421%
Monoclonal Antibody
211%
+ 283 programs with unclassified modality

On Market (5)

Approved therapies currently available

Amgen
CORLANORApproved
ivabradine
Amgen
oral2019
U
IVABRADINE HYDROCHLORIDEApproved
ivabradine
Unknown Company
oral2022
Boehringer Ingelheim
JARDIANCEApproved
empagliflozin
Boehringer Ingelheim
Sodium-Glucose Cotransporter 2 Inhibitor [EPC]oral2014
U
LANOXINApproved
digoxin
Unknown Company
Cardiac Glycoside [EPC]oral1997
U
LANOXIN PEDIATRICApproved
digoxin
Unknown Company
Cardiac Glycoside [EPC]injection1954

Competitive Landscape

52 companies ranked by most advanced pipeline stage

Rhythm Pharmaceuticals
67 programs
2
2
2
7
Access ArmPhase 41 trial
CRTPhase 41 trial
CRT + AOPPhase 41 trial
Conducted AF-Response AlgorithmPhase 41 trial
LV dp/dt pressure measurementPhase 41 trial
+62 more programs
Active Trials
NCT00980057Completed522Est. Mar 2012
NCT01059175Completed84Est. Sep 2014
NCT03099655Completed471Est. May 2019
+64 more trials
Abbott
AbbottABBOTT PARK, IL
59 programs
1
1
2
6
CRT onPhase 41 trial
Device programmingPhase 41 trial
Electrical optimization by RVLV Conduction Time with VectSelectPhase 41 trial
Quadripolar LV leadPhase 43 trials
Simultaneous VV PacingPhase 41 trial
+54 more programs
Active Trials
NCT00187252Completed380Est. Jun 2008
NCT00875732Completed22Est. Jan 2011
NCT02470312Terminated578Est. Feb 2018
+69 more trials
Biotronik
BiotronikGermany - Berlin
24 programs
1
3
ICD/CRT-DPhase 41 trial
Intracardiac Impedance Measurement AlgorithmPhase 41 trial
Intrathoracic impedance measurementPhase 41 trial
Implantable Cardioverter Defibrillator with Cardiac Resynchronization TherapyPhase 2/31 trial
A Prospective Pilot Study (BIO|SELECT Pilot)N/A1 trial
+19 more programs
Active Trials
NCT03337763Completed201Est. Oct 2019
NCT03891329Completed130Est. Sep 2021
NCT05142293Active Not Recruiting354Est. May 2026
+21 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
19 programs
1
8
2
Empagliflozin at a dose of 10 mg/dayPhase 41 trial
SGLT2i, beta blocker, ARNI, MRA, MTDPhase 41 trial
EmpagliflozinPhase 3Small Molecule1 trial
EmpagliflozinPhase 3Small Molecule1 trial
EmpagliflozinPhase 3Small Molecule1 trial
+14 more programs
Active Trials
NCT05377190Completed175Est. Oct 2023
NCT05350202Completed3,431Est. Jul 2024
NCT04648852Completed36,511Est. Jun 2023
+16 more trials
AstraZeneca
12 programs
2
1
Dapagliflozin 10mg TabPhase 41 trial
AZD3427Phase 11 trial
AZD5462 film-coated tabletPhase 11 trial
Dapagliflozin 10 milligrams [Farxiga]N/A1 trial
Economic Evaluation of Heart Failure Management in Colombian ClinicsN/A1 trial
+7 more programs
Active Trials
NCT04591639Recruiting160Est. Jul 2028
NCT01084564Completed300Est. Jun 2008
NCT04865406Completed1,221Est. Aug 2024
+9 more trials
Novartis
NovartisBASEL, Switzerland
7 programs
2
ACEI/ARBPhase 41 trial
sacubitril/valsatranPhase 41 trial
Guideline Directed Medical Therapy in Patients With Heart FailureN/A
Heart Failure in Norway: Clinical Characteristics, Mortality and Health Care Resource UseN/A1 trial
Identifying Diuretic Resistance in Patients With Acute Heart FailureN/A1 trial
+2 more programs
Active Trials
NCT04398563Unknown14,998Est. Dec 2023
NCT02751242Completed75Est. Jul 2017
NCT04143919Completed317Est. Jun 2021
+7 more trials
Novo Nordisk
7 programs
2
2
2
1
Hydralazine Isosorbide DinitratePhase 41 trial
ZiltivekimabPhase 3Monoclonal Antibody1 trial
ZiltivekimabPhase 3Monoclonal Antibody1 trial
CDR132LPhase 21 trial
CDR132LPhase 21 trial
+2 more programs
Active Trials
NCT04045405Completed28Est. Jun 2020
NCT07218627Recruiting36Est. Jan 2027
NCT06979375Recruiting200Est. Jan 2028
+4 more trials
Amgen
2 programs
1
1
CORLANOR(ivabradine)Phase 43 trials
AMG 986Phase 11 trial
Active Trials
NCT03318809Completed12Est. Apr 2018
NCT03619187Withdrawn0Est. Feb 2020
NCT03456856Completed30Est. May 2019
+1 more trials
Astellas
AstellasChina - Shenyang
1 program
1
ConivaptanPhase 43 trials
Active Trials
NCT00924014Unknown8Est. Mar 2010
NCT00806910Withdrawn0Est. Feb 2010
NCT00727090Terminated6Est. Feb 2010
Teva
1 program
1
DigoxinPhase 41 trial
Active Trials
NCT03783429Unknown982Est. Jul 2025
Cytokinetics
CytokineticsSOUTH SAN FRANCISCO, CA
8 programs
1
5
2
Omecamtiv MecarbilPhase 31 trial
Omecamtiv MecarbilPhase 31 trial
CK-1827452Phase 21 trial
CK-1827452Phase 21 trial
CK-1827452Phase 21 trial
+3 more programs
Active Trials
NCT01737866Completed13Est. May 2013
NCT00748579Terminated2Est. Jul 2009
NCT00624442Completed45Est. Feb 2009
+5 more trials
Sanofi
2 programs
1
SotagliflozinPhase 3Small Molecule5 trials
Extensive phenotypingN/A1 trial
Active Trials
NCT04189029Active Not Recruiting175Est. Dec 2025
NCT03909451Completed24Est. Aug 2019
NCT03802487Completed6Est. Mar 2019
+3 more trials
Takeda
2 programs
1
Candesartan and standard chronic heart disease therapyPhase 31 trial
Prospective Observation of Cardiac Safety With Proteasome InhibitionN/A1 trial
Active Trials
NCT02178579Completed95Est. Jul 2019
NCT00843154Terminated571Est. Jul 2008
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
1
1
EmpagliflozinPhase 3Small Molecule
LY3540378Phase 21 trial
Active Trials
NCT05592275Terminated332Est. Jan 2025
M&
Merck & Co.RAHWAY, NJ
7 programs
4
1
1
Vericiguat tabletPhase 2/31 trial
ZepatierPhase 1/21 trial
Blood DrawPhase 11 trial
VericiguatPhase 11 trial
VericiguatPhase 11 trial
+2 more programs
Active Trials
NCT06847438Recruiting4,000Est. Jun 2026
NCT02364752Withdrawn0Est. Nov 2016
NCT04722484Completed39Est. Jan 2015
+4 more trials
Abiogen
AbiogenItaly - Pisa
1 program
1
CHOLECALCIFEROLPhase 2/31 trial
Active Trials
NCT01477801UnknownEst. Sep 2012
Bayer
9 programs
2
2
FinerenonePhase 21 trial
Neladenoson bialanatePhase 21 trial
BAY60-4552Phase 11 trial
BAY94-8862Phase 11 trial
AVIVO Mobile Patient ManagementN/A1 trial
+4 more programs
Active Trials
NCT03507439Completed27Est. Mar 2021
NCT02299960Completed101Est. Oct 2015
NCT05036967Completed1,000Est. Nov 2022
+5 more trials
Cardurion Pharmaceuticals
3 programs
3
CRD-740Phase 21 trial
TovinontrinePhase 21 trial
TovinontrinePhase 21 trial
Active Trials
NCT05409183TerminatedEst. Jul 2023
NCT06215586CompletedEst. Sep 2025
NCT06215911CompletedEst. Oct 2025
Debiopharm
2 programs
1
1
IstaroximePhase 21 trial
IstaroximePhase 11 trial
Active Trials
NCT00869115Withdrawn
NCT00838253Withdrawn
Lantheus Medical Imaging
2 programs
1
1
LMI 1195Phase 21 trial
LMI 1195-101Phase 11 trial
Active Trials
NCT00891241CompletedEst. Nov 2009
NCT01085175WithdrawnEst. Feb 2011
Capricor Therapeutics
2 programs
1
1
CenderitidePhase 2Peptide1 trial
CenderitidePhase 1/2Peptide1 trial
Active Trials
NCT02603614Completed8Est. Mar 2016
NCT02359227Completed14Est. Apr 2015
Regeneron
RegeneronTARRYTOWN, NY
2 programs
2
REGN5381Phase 21 trial
REGN5381Phase 21 trial
Active Trials
NCT06237309Terminated89Est. Dec 2025
NCT05353166Completed59Est. Jun 2025
Genomics
1 program
1
QGC001Phase 21 trial
Active Trials
NCT02780180Terminated23Est. Sep 2018
HELP Therapeutics
HELP TherapeuticsChina - Nanjing
4 programs
4
HiCM-188 therapyPhase 1/21 trial
hPSC-CM TherapyPhase 1/21 trial
hiPSC-CM therapyPhase 1/21 trial
low dose CABG+iPSC-CMsPhase 1/21 trial
Active Trials
NCT06340048Active Not RecruitingEst. May 2027
NCT03763136CompletedEst. Oct 2024
NCT05223894UnknownEst. Dec 2025
+1 more trials
Trevena
TrevenaPA - Chesterbrook
2 programs
1
1
TRV120027Phase 1/21 trial
TRV120027Phase 11 trial
Active Trials
NCT01444872Completed17Est. Jun 2012
NCT01187836Completed33Est. Mar 2012
Repairon
RepaironGermany - Göttingen
1 program
1
EHM implantationPhase 1/21 trial
Active Trials
NCT04396899RecruitingEst. Dec 2027
Precigen
PrecigenGERMANTOWN, MD
1 program
1
INXN-4001Phase 11 trial
Active Trials
NCT03409627CompletedEst. Aug 2020
Thryv Therapeutics
Thryv TherapeuticsQC - Montreal
1 program
1
THRV-1268Phase 11 trial
Active Trials
NCT07186946CompletedEst. Oct 2025
Francis Medical
Francis MedicalMN - Maple Grove
1 program
1
clenbuterolPhase 11 trial
Active Trials
NCT00585546TerminatedEst. Mar 2010
Impulse Dynamics
8 programs
CCM OPEN HF RegistryN/A1 trial
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini SystemN/A1 trial
Effects of CCM-therapy in Patients With Heart FailureN/A1 trial
OPTIMIZERN/A1 trial
OPTIMIZER Smart SystemN/A1 trial
+3 more programs
Active Trials
NCT07112924RecruitingEst. Aug 2036
NCT05064709RecruitingEst. Feb 2029
NCT02895048CompletedEst. Nov 2013
+5 more trials

+22 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
AstraZenecaDapagliflozin 10mg Tab
Boehringer IngelheimSGLT2i, beta blocker, ARNI, MRA, MTD
NovartisACEI/ARB
TevaDigoxin
Novartissacubitril/valsatran
Novo NordiskHydralazine Isosorbide Dinitrate
Boehringer IngelheimEmpagliflozin at a dose of 10 mg/day
Amgenivabradine
Novartissacubitril/valsartan
Novartissacubitril/valsartan
AbbottWarfarin
Novartissacubitril/valsartan
Novartissacubitril/valsartan
Amgenivabradine
Novartissacubitril/valsartan

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 32,554 patients across 50 trials

NCT05741658AstraZenecaDapagliflozin 10mg Tab

The Fontan Dapagliflozin Pilot Study

Start: Nov 2023Est. completion: Mar 202629 patients
Phase 4Enrolling By Invitation
NCT05734690Boehringer IngelheimSGLT2i, beta blocker, ARNI, MRA, MTD

COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

Start: May 2023Est. completion: Jun 2025503 patients
Phase 4Completed
NCT04491136NovartisACEI/ARB

Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)

Start: Nov 2020Est. completion: Jun 2023201 patients
Phase 4Terminated
NCT03783429TevaDigoxin

Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands

Start: Jul 2020Est. completion: Jul 2025982 patients
Phase 4Unknown
NCT03300427Novartissacubitril/valsatran

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients

Start: Jul 2018Est. completion: Mar 202255 patients
Phase 4Completed
NCT03514108Novo NordiskHydralazine Isosorbide Dinitrate

DANHEART (H-HeFT and Met-HeFT)

Start: Mar 2018Est. completion: Dec 20251,100 patients
Phase 4Completed
NCT03271879Boehringer IngelheimEmpagliflozin at a dose of 10 mg/day

Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients

Start: Feb 2018Est. completion: Jun 2020128 patients
Phase 4Unknown
NCT03456856Amgenivabradine

A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.

Start: Sep 2017Est. completion: May 201930 patients
Phase 4Completed
NCT03119623Novartissacubitril/valsartan

Comparing ARNI With ACE Inhibitor on Endothelial Function

Start: Jun 2017Est. completion: Aug 20190
Phase 4Withdrawn
NCT02970669Novartissacubitril/valsartan

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

Start: Dec 2016Est. completion: Mar 2018140 patients
Phase 4Completed
NCT02836652AbbottWarfarin

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

Start: Nov 2016Est. completion: Jul 201972 patients
Phase 4Completed
NCT02887183Novartissacubitril/valsartan

Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.

Start: Oct 2016Est. completion: Oct 2018794 patients
Phase 4Completed
NCT02788656Novartissacubitril/valsartan

Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

Start: Sep 2016Est. completion: Nov 20184 patients
Phase 4Terminated
NCT02827500Amgenivabradine

Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)

Start: Jul 2016Est. completion: Oct 2018104 patients
Phase 4Completed
NCT02554890Novartissacubitril/valsartan

Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

Start: Apr 2016Est. completion: Jul 2018887 patients
Phase 4Completed
NCT02690974Novartissacubitril/valsartan

Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting

Start: Mar 2016Est. completion: Nov 2017302 patients
Phase 4Completed
NCT02195843AbbottElectrical optimization by RVLV Conduction Time with VectSelect

Quadripolar Leads for the Management of Heart Failure Patients in the Middle East

Start: Aug 2014Est. completion: Aug 2016389 patients
Phase 4Unknown
NCT01711281BiotronikIntracardiac Impedance Measurement Algorithm

Monitoring of Hemodynamics in Heart Failure Patients by Intracardiac Impedance Measurement

Start: Oct 201268 patients
Phase 4Completed
NCT01295840AbbottCardiac Resynchronization Therapy

Quartet Lead and Resynchronization Therapy Options

Start: Jan 2011Est. completion: Sep 201251 patients
Phase 4Completed
NCT01221649BiotronikICD/CRT-D

Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement in Japan (J-HomeCARE II)

Start: Jun 2010Est. completion: Feb 2014198 patients
Phase 4Completed
NCT00964938AbbottQuadripolar LV lead

Multisite Pacing With a Quadripolar Lead

Start: Aug 200935 patients
Phase 4Completed
NCT00847288Rhythm PharmaceuticalsMonthly Review Arm

OptiVol® Care Pathway

Start: Mar 2009Est. completion: May 20111,682 patients
Phase 4Completed
NCT00821938Rhythm PharmaceuticalsLV dp/dt pressure measurement

Cardiac Resynchronization Therapy (CRT)-Narrow-dp/Dt-Study

Start: Nov 2008Est. completion: Jul 201630 patients
Phase 4Completed
NCT01434615Rhythm PharmaceuticalsCRT

Medtronic South Asian Systolic Heart Failure Registry

Start: Oct 2008Est. completion: Dec 2015502 patients
Phase 4Completed
NCT00806910AstellasConivaptan

Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion

Start: Oct 2008Est. completion: Feb 20100
Phase 4Withdrawn
NCT00769457Rhythm PharmaceuticalsAccess Arm

OptiLink HF Study: Optimization of Heart Failure Management Using Medtronic OptiVol Fluid Status Monitoring and CareLink Network

Start: Sep 2008Est. completion: Nov 20141,002 patients
Phase 4Completed
NCT00727090AstellasConivaptan

Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients

Start: Aug 2008Est. completion: Feb 20106 patients
Phase 4Terminated
NCT00711360BiotronikIntrathoracic impedance measurement

Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement (HomeCARE II)

Start: Jul 2008Est. completion: Sep 2012303 patients
Phase 4Completed
NCT00626093AbbottCardiac Resynchronization Therapy

'Effect of CRT on Defibrillation Threshold Estimates' Study

Start: Jan 2008Est. completion: Apr 201077 patients
Phase 4Completed
NCT00489177AbbottCardiac Resynchronization Therapy

Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy.

Start: Jun 2007Est. completion: Nov 2012461 patients
Phase 4Completed
NCT00480077Rhythm PharmaceuticalsProgramming

Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial)

Start: Mar 2007Est. completion: Jan 2011335 patients
Phase 4Terminated
NCT00551499Rhythm PharmaceuticalsCRT + AOP

Cardiac Resynchronisation Therapy in Combination With Overdrive Pacing in the Treatment of Central Sleep Apnea in CHF

Start: Jun 2005Est. completion: Dec 200644 patients
Phase 4Completed
NCT00187200AbbottSimultaneous VV Pacing

Response of Cardiac Resynchronization Therapy Optimization With Ventricle to Ventricle Timing in Heart Failure Patients

Start: Jan 2005Est. completion: Apr 2010816 patients
Phase 4Completed
NCT00170313Rhythm PharmaceuticalsConducted AF-Response Algorithm

CORE: Study to Evaluate the Conducted AF-Response-Algorithm in Patients Suffering From Heart Failure and Atrial Fibrillation

Start: Dec 2003Est. completion: Jan 2007100 patients
Phase 4Terminated
NCT00900549AbbottCRT on

Evaluation of Resynchronization Therapy for Heart Failure

Start: Oct 2003Est. completion: Jul 2011120 patients
Phase 4Terminated
NCT00901212AbbottDevice programming

Evaluation of Resynchronization Therapy for Heart Failure (EARTH)

Start: Oct 2003Est. completion: Feb 2010120 patients
Phase 4Completed
NCT00206856AbbottTriage® B-Type Natriuretic Peptide

Rapid Assessment of Bedside BNP In Treatment of Heart Failure (RABBIT)

Start: Jul 2003Est. completion: Apr 2006720 patients
Phase 4Terminated
NCT06935370Boehringer Ingelheimvicadrostat

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

Start: May 2025Est. completion: Feb 20294,200 patients
Phase 3Recruiting
NCT06736574CytokineticsOmecamtiv Mecarbil

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Start: Dec 2024Est. completion: Dec 20271,800 patients
Phase 3Recruiting
NCT06424288Boehringer Ingelheimvicadrostat

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Start: Jun 2024Est. completion: May 20286,000 patients
Phase 3Recruiting
NCT06200207Novo NordiskZiltivekimab

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

Start: Apr 2024Est. completion: Jan 2027680 patients
Phase 3Recruiting
NCT06149104Novartissacubitril/valsartan

A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study

Start: Dec 2023Est. completion: Aug 20248 patients
Phase 3Completed
NCT05636176Novo NordiskZiltivekimab

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Start: May 2023Est. completion: Jul 20275,600 patients
Phase 3Recruiting
NCT04157751Boehringer IngelheimEmpagliflozin

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

Start: May 2020Est. completion: Jun 2021530 patients
Phase 3Completed
NCT03988634Novartissacubitril/valsartan

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Start: Jun 2019Est. completion: Dec 2022467 patients
Phase 3Completed
NCT03785405Novartissacubitril/valsartan

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Start: May 2019Est. completion: Dec 2023216 patients
Phase 3Completed
NCT03884504Rhythm PharmaceuticalsVentricular Assist Device System

MDT-1118 Japan DT Study

Start: May 2019Est. completion: Oct 202210 patients
Phase 3Completed
NCT03761134SanofiSotagliflozin

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

Start: Nov 2018Est. completion: Apr 2020377 patients
Phase 3Terminated
NCT03760965SanofiSotagliflozin

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise

Start: Nov 2018Est. completion: Apr 2020276 patients
Phase 3Terminated
NCT03619187Amgenivabradine

An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients

Start: Nov 2018Est. completion: Feb 20200
Phase 3Withdrawn

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Therapeutic Area Partner-Heart Failure-(Abu Dhabi and Alain)

Novartis
Abu Dhabi
2d ago

Directeur Medical Regional (MSL) cardio pulmonaire région AURA H/F

Merck & Co.
FRA - Ile-de-France - Paris (Cour Michelet)
4d ago

Pharmaceutical Sales Specialist, CVRM Primary Care - Columbus, GA

AstraZeneca
Columbus - GA, US
5d ago
$77K - $178K/yr

Director Global Market Access PAH & Rare Diseases

Merck & Co.
USA - New Jersey - Rahway
6d ago
$191K - $300K/yr

Pharmaceutical Sales Specialist, CVRM Primary Care - Naples, FL

AstraZeneca
US
6d ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

19 late-stage (Phase 3) programs — potential near-term approvals
5 actively recruiting trials targeting 32,554 patients
30 companies competing in this space

Related Indications

Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)Atherosclerosis(27)